Form 6-K GLAXOSMITHKLINE PLC For: Feb 02
FORM 6-K/A
�
�
SECURITIES AND EXCHANGE COMMISSION(
Washington D.C. 20549
�
�
Report of Foreign Issuer
�
�
Pursuant to Rule 13a-16 or 15d-16 of(
athe Securities Exchange Act of 1934
�
�
�
For period ending�February 2015
�
GlaxoSmithKline plc
(Name of registrant)(
�
�
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)(
�
�
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F(
�
�
Form 20-F x��� �Form 40-F(
�
--(
�
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.(
�
�
Yes����� No x
--
�
GlaxoSmithKline plc
�
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
�
In accordance with DTR 3.1.4 R(1)(a) and (c) GlaxoSmithKline plc (GSK) was advised on 2 February 2015 of the following increase in the notional allocation of GSK American Depositary Shares (ADSs) on 30 January 2015, at a price of $44.00 per ADS, following the revaluation of the cash element of the notional investment held within the GSK 401K plan:
�
|
Director/PDMR
|
Number of ADSs
|
|
Dr M M Slaoui
|
20
|
�
|
Connected person
|
Number of ADSs
|
|
Dr K Slaoui (connected person of Dr M M Slaoui)
|
5
|
�
V A Whyte
Company Secretary
�
2 February 2015
�
SIGNATURES
�
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.(
�
�
GlaxoSmithKline plc
(Registrant)(
Date:�February 02,�2015�
�
�
By:�VICTORIA WHYTE
----------------------
�
�
Victoria�Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc